SCHEMBL29565864

SCHEMBL29565864

CC(C)(C)OC(=O)N1C[C@@H](F)C[C@H]1CNc1ccc(Cl)nn1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 4/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ ABCB1 P08183 1/20 0.35
▸ PRMT5 O14744 1/20 0.34
▸ TSHR P16473 4/20 0.34
▸ POLB P06746 2/20 0.34
▸ ALDH1A1 P00352 2/20 0.34
▸ CYP1A2 P05177 1/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ CYP2C19 P33261 1/20 0.34
▸ CCNT1 O60563 1/20 0.34
▸ CDK9 P50750 1/20 0.34
▸ DPP4 P27487 2/20 0.33
▸ HSD11B1 P28845 1/20 0.33
▸ EP300 Q09472 1/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ NPSR1 Q6W5P4 1/20 0.33
▸ USP30 Q70CQ3 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29565667 1.00 LMNA (0.36) LMNAKMT2AABCB1PRMT5TSHR
SCHEMBL22670584 1.00 LMNA (0.36) LMNAKMT2AABCB1PRMT5TSHR
SCHEMBL22671985 1.00 LMNA (0.36) LMNAKMT2AABCB1PRMT5TSHR
SCHEMBL16040729 0.84 CCNT1 (0.38) LMNAABCB1PRMT5TSHRPOLB
SCHEMBL16040728 0.84 CCNT1 (0.38) LMNAABCB1PRMT5TSHRPOLB
SCHEMBL22655136 0.84 DPP4 (0.37) LMNAPOLBALDH1A1DPP4MAPT
SCHEMBL22654944 0.84 DPP4 (0.37) LMNAPOLBALDH1A1DPP4MAPT
SCHEMBL23545080 0.77 NR1H2 (0.51) LMNAKMT2APRMT5CCNT1CDK9
SCHEMBL20936864 0.77 NR1H2 (0.51) LMNAKMT2APRMT5CCNT1CDK9
SCHEMBL29501504 0.77 NR1H2 (0.51) LMNAKMT2APRMT5CCNT1CDK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250270188-A1 NLRP3 INFLAMMASOME INHIBITORS NOVARTIS AG (CH) 2025-08-28 — — US disclosed
US-12139471-B2 NLRP3 inflammasome inhibitors NOVARTIS AG (CH) 2024-11-12 — — US disclosed
US-20220251067-A1 NLRP3 INFLAMMASOME INHIBITORS NOVARTIS AG (CH) 2022-08-11 — — US disclosed
US-11254653-B2 NLRP3 inflammasome inhibitors NOVARTIS AG (CH) 2022-02-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11254653-B2 NLRP3 inflammasome inhibitors NLRP3, NLRP1, NOD1 LMNA 986/4885KMT2A 3715/4885ABCB1 234/4885
US-20220251067-A1 NLRP3 INFLAMMASOME INHIBITORS NLRP3, NLRP1, NOD1 LMNA 986/4885KMT2A 3715/4885ABCB1 234/4885
US-12139471-B2 NLRP3 inflammasome inhibitors NLRP3, NLRP1, NOD1 LMNA 986/4885KMT2A 3715/4885ABCB1 234/4885
US-20250270188-A1 NLRP3 INFLAMMASOME INHIBITORS NLRP3, NLRP1, NOD1 LMNA 986/4885KMT2A 3715/4885ABCB1 234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback